<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01199224</url>
  </required_header>
  <id_info>
    <org_study_id>M11-846</org_study_id>
    <nct_id>NCT01199224</nct_id>
  </id_info>
  <brief_title>To Determine the Food Effect and Bioavailability of Three Formulations of Veliparib in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the bioavailability of three veliparib formulations in subjects with solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess the oral bioavailability of veliparib</measure>
    <time_frame>Up to 4 weeks.</time_frame>
    <description>Assess the relative bioavailability of Formulation A, Formulation B and Formulation C with or without food measured using area under the plasma concentration-time curve (AUC), the maximum observed plasma concentration (Cmax), and time to Cmax (Tmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of veliparib in patients with solid tumors</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>Safety and tolerability will be assessed through clinical laboratory tests, electrocardiograms (ECGs), vital signs, physical exams and adverse event assessments</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veliparib</intervention_name>
    <description>veliparib formulation A</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veliparib</intervention_name>
    <description>veliparib formulation B</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veliparib</intervention_name>
    <description>veliparib formulation C</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>ABT-888</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>veliparib</intervention_name>
    <description>veliparib formulation C</description>
    <arm_group_label>Arm D</arm_group_label>
    <other_name>ABT-888</other_name>
    <other_name>velaparib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects with cytologically/histologically confirmed solid tumors that are either
             relapsed or refractory to standard therapy or there is no known effective therapy.

          2. In the opinion of the Investigator, life expectancy is 12 weeks or greater.

          3. Subjects with known brain metastases must have clinically controlled neurologic
             symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of
             stable neurologic function and no evidence of central nervous system (CNS) disease
             progression as determined by computed tomography (CT) scan or magnetic resonance
             imaging (MRI) within 21 days prior to the first dose of study drug.

          4. Subject has an Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2.

          5. Subject must have adequate bone marrow, renal and hepatic function per local
             laboratory reference range.

        Exclusion Criteria:

          1. The subject is unable to swallow capsules or has nausea or vomiting.

          2. Female subject is pregnant or breast-feeding.

          3. Subject has a history of or an active medical condition(s) that affects absorption or
             motility (e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome).

          4. History of gastric surgery, vagotomy, bowel resection (except for left hemicolectomy)
             or any surgical procedure that might interfere with gastrointestinal motility,
             potentiometric hydrogen ion concentration (pH) or absorption.

          5. Subject exhibits evidence of other clinically significant uncontrolled condition(s)
             including, but not limited to:

               -  Known seizure disorder that is uncontrolled over the past month

               -  Active uncontrolled infection

               -  Unstable angina pectoris or cardiac arrhythmia

               -  Psychiatric illness/social situation that would limit compliance with study
                  requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bhardwaj Desai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <results_reference>
    <citation>Mostafa NM, Chiu YL, Rosen LS, Bessudo A, Kovacs X, Giranda VL. A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors. Cancer Chemother Pharmacol. 2014 Sep;74(3):583-91. doi: 10.1007/s00280-014-2529-2. Epub 2014 Jul 23.</citation>
    <PMID>25053388</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>veliparib</keyword>
  <keyword>refractory</keyword>
  <keyword>relapsed</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Veliparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

